Compare RFL & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RFL | CRBU |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | N/A | 97 |
| Industry | Real Estate | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.1M | 139.4M |
| IPO Year | 2017 | 2021 |
| Metric | RFL | CRBU |
|---|---|---|
| Price | $2.00 | $1.34 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $10.75 |
| AVG Volume (30 Days) | 106.8K | ★ 1.1M |
| Earning Date | 06-10-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 28.28 | 3.64 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $917,000.00 | N/A |
| Revenue This Year | N/A | $1.63 |
| Revenue Next Year | N/A | $10.93 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 43.96 | N/A |
| 52 Week Low | $1.12 | $1.25 |
| 52 Week High | $3.96 | $3.53 |
| Indicator | RFL | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 38.19 | 38.73 |
| Support Level | $1.86 | N/A |
| Resistance Level | $2.16 | $1.72 |
| Average True Range (ATR) | 0.20 | 0.07 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 3.84 | 22.67 |
Rafael Holdings Inc is a biotechnology firm that develops pharmaceuticals and invests in clinical and early-stage companies in pharmaceuticals and medical devices. Trappsol Cyclo is in Phase 3 trials for Niemann-Pick Disease Type C1. The company focuses on completing these trials, seeking regulatory approval, and commercializing the product. It also invests in portfolio companies including Cyclo, LipoMedix, Barer, Rafael Medical Devices, Cornerstone, and Day Three, targeting therapeutics for unmet medical needs. The business operates through three segments: Healthcare, Infusion Technology, and Real Estate. Operations are based in the United States and Israel.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.